EU Q&A on Importation of APIs
The Falsified Medicines Directive came into force in Europe in January 2013. Among the Directive’s requirements is the stipulation that APIs imported into the European Union meet equivalent GMPs to those applied in the EU. To implement this requirement, manufacturers must obtain certification from the competent authority in the country where the API is manufactured that they were made in compliance with GMPs equivalent to those of the EU. Alternatively, countries of origin may apply for exemption from this rule for APIs manufactured within their borders.
To assist manufacturers, the European Commission published version 5.0 Questions and Answers regarding Importation of Active Substances for Medicinal Products for Human Use on 13 November 2013 which adds two new questions and answers — 33 and 34:
33. QUESTION:WHAT HAPPENS WHEN AN ACTIVE SUBSTANCE MANUFACTURING SITE COVERED BY A WRITTEN CONFIRMATION IS FOUND GMP NON-COMPLIANT FOLLOWING AN INSPECTION BY A EU MEMBER STATE?
Answer: A statement of GMP non-compliance issued by a EU Member State for a specific site and API supersedes the corresponding written confirmation until the noncompliance is resolved.
34. QUESTION: WHERE CAN I FIND A LIST OF ACTIVE SUBSTANCE MANUFACTURING SITES THAT RECEIVED STATEMENTS OF GMP NON-COMPLIANCE?
Answer: Statements of GMP non-compliance are stored in the EudraGMDP database (http://eudragmdp.eudra.org/inspections/displayWelcome.do). They are currently accessible only by EU national competent authorities, but are expected to become publicly available by end of 2013. Until then, a list of active manufacturing sites that received a statement of GMP noncompliance can be found here: http://ec.europa.eu/health/humanuse/quality/index_en.htm#ias.
The EudraGMDP database referenced above now includes summary reports and reasons for non-compliance status identified during inspections. It may be found at: http://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance